🔎 Trials Near Me

Dachaigh › Scleroderma Sgaoilte › Illinois

Sgrùdaidhean clionaigeach Scleroderma Sgaoilte ann an Illinois

Tha 8 sgrùdaidhean airson Scleroderma Sgaoilte a’ lorg phàirtichean aig làraichean ann an Illinois.

Bailtean ann an Illinois

Teacsa sgrùdaidh oifigeil (Beurla)

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  • University of Chicago Hospitals, Chicago
A’ fastadhÌre 2
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06470048

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • The University of Chicago Medical Center, Chicago
A’ fastadhÌre 1
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Chicago
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT05878717

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  • Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
A’ fastadhÌre 1
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT06925542

Platform Clinical Study for Conquering Scleroderma

  • The University of Chicago Medical Center (UCMC), Chicago
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
A’ fastadhÌre 2/3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Chicago
A’ fastadhÌre 1/2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 7 Lùna 2026 · NCT06733935

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Willowbrook, Willowbrook
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 31 Iuch 2026 · NCT06991114

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.